Neurizon Therapeutics (ASX:NUZ) has reported positive topline results from the Open-Label Extension study of its lead candidate NUZ-001 for the treatment of amyotrophic lateral sclerosis, which is the primary form of motor neurone disease. …
Neurizon's NUZ-001 OLE study demonstrates long-term safety and efficacy signals
August 20, 2025 Australian Biotech
Latest Video
New Stories
-
LTR Pharma says new study confirms faster onset of intranasal treatment
August 20, 2025 - - BioPharma -
Neurizon's NUZ-001 OLE study demonstrates long-term safety and efficacy signals
August 20, 2025 - - Australian Biotech -
US FDA grants orphan drug designation to Invion's INV043
August 20, 2025 - - Australian Biotech -
AI added to the work of HTA Review Implementation Advisory Group
August 20, 2025 - - Latest News -
CSL launches strategic initiatives with planned separation of Seqirus
August 20, 2025 - - Latest News -
Former Queensland Premier appointed to chair Brandon BioCatalyst
August 19, 2025 - - Australian Biotech -
Lilly launches new initiative with Monash University to improve gaps in obesity management
August 18, 2025 - - Latest News